Efficacy of platinum plus cyclophosphamide in patients with epithelial ovarian cancer.

Objectives: To determine the response rate (RR), 5-year progression-free survival (PFS), and the 5-year survival rate (SVR) of epithelial ovarian cancer patients who received platinum plus cyclophosphamide as adjuvant postoperative chemotherapy.

Material And Method: Epithelial ovarian cancer patients who underwent tumor debulking surgery and received platinum plus cyclophosphamide as adjuvant chemotherapy at Vajira Hospital from January 1995 to December 2003 were identified. All clinical and pathological data were reviewed

Results: Among 114 patients included in the present study, 101 patients were evaluable for response.